HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Drug Pipeline
Meta-analysis
Meta-analysis shows salidroside improves metabolic markers in rodent NAFLD models
New Natural Compound Could Lower Liver Fat in Early Tests
This meta-analysis synthesizes data from 12 eligible animal studies investigating salidroside in rodent NAFLD models. The authors report sig…
A review of animal studies suggests a specific compound may help heal fatty livers.
Frontiers
Apr 24, 2026
Allergy & Immunology
Sys. Review
Narrative review synthesizes evidence on NAFLD, NASH, and viral hepatitis management without reported trial data.
Your Liver Has an Immune Army — and It Can Turn Against You
This narrative review addresses management considerations for nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH),…
Your liver's own immune cells can turn on itself to cause permanent scarring, but scientists are now mapping these cells to stop the damage …
Frontiers
Apr 18, 2026
Neurology
Meta-analysis
Dihydromyricetin reduces hepatic lipids and improves metabolic markers in murine MASLD models
A Simple Tea Ingredient Could Help Your Liver
A preclinical systematic review and meta-analysis of 14 controlled murine studies in diet-induced MASLD/NAFLD models found that dihydromyric…
A simple tea ingredient called dihydromyricetin reduced liver fat, improved blood sugar, and lowered cholesterol in mice with fatty liver di…
Frontiers
Apr 14, 2026
Gastroenterology
Phase II
Phase 2 trial tests three Vitamin E doses versus placebo in 200 adults with NAFLD
Vitamin E dosing study in 200 adults with fatty liver disease completes trial
A phase 2 randomized controlled trial enrolled 200 adults with NAFLD to compare three doses of Vitamin E (200 IU, 400 IU, 800 IU) with place…
A completed trial on Vitamin E for fatty liver disease has finished, but the results showing if the doses helped or caused harm are not yet …
CT.gov
Mar 30, 2026